§6 Findings: Federalism & Legal Mechanics

Date: 2026-08-03. Tests seed hypotheses H6.1–H6.2.

Hypothesis verdicts

H6.1 NARROWED 2026-08-10 by the Phase 2 steelman pass (steelman-log.md, Steelman A-3). The finding below is right that the constraint is federal and wrong that the venue is. For the filing's own headline architecture, the executable pathway turned out to be state-by-state §1115 demonstration authority: CMS has approved contingency-management coverage in California, Washington, Montana, Hawaii and Delaware, at approved incentive maxima of 596–1,092 — Washington's being 1.80× the 2025 patient-engagement safe-harbor cap, and Delaware's raised from $599 to $750 with CMS's approval. Two more states are pending, one was denied. Application to approval ran about a year; California has been delivering since March 2023. So "no state or local government can independently fix any of them" does not hold for the one item this filing recommends: states have been fixing it, one demonstration at a time, since 2022. See ws04-findings.md and method/sources/cm-delivery-pathways-and-state-medicaid.md.

H6.1 (drugs' binding legal constraints are mostly federal — the inverse of housing's local/state finding) — Supported, with a real nuance. Every mechanism examined — CSA scheduling authority, the methadone OTP registration requirement, the Medicaid IMD exclusion, the anti-kickback/beneficiary-inducement ceiling — is federal statute or federal agency regulation; no state or local government can independently fix any of them. Cannabis is the interesting partial exception: 24 states have made a de facto policy choice (legalization) running directly counter to residual federal law, giving states real practical leverage over enforcement/market reality at the retail level. But even there, what states categorically cannot fix — federal §280E tax treatment, banking access, the schedule itself — remains federally load-bearing, and is exactly what keeps cannabis businesses cash-only and undercapitalized nationwide. The binding-constraint layer is federal even where the practical-policy layer has become substantially state-driven — a clean inversion of GBMT-2's housing finding, as the protocol's seed hypothesis anticipated.

H6.2 (a material fraction of the reform agenda is rulemaking-executable, no statute needed) — Supported, but narrower than a strong reading suggests. Real rulemaking-only levers exist and some have already been pulled — 2024's methadone take-home liberalization, the April 2026 narrow cannabis Schedule III move, CMS's 1115 IMD waivers (38 states + D.C. as of April 2026), the §438.6(e) managed-care carve-out, and OIG's clear standing authority (from a 1987 statute) to create a contingency-management-specific safe harbor without new legislation. But the two items with the largest structural leverage — ending the methadone OTP monopoly, and a durable/universal fix to the IMD exclusion — are statutorily locked in a way agencies cannot unilaterally undo, and cannabis's banking/tax/interstate-commerce problems are squarely congressional.

Cannabis rescheduling — much further along than Phase 0 assumed, and actively contested

CONFIRMED AT PRIMARY TIER 2026-08-10. This section's confidence note (below) conceded it rested on converging law-firm client alerts rather than Federal Register text, and method/sources/UNOBTAINED.md listed this order as the filing's highest-priority unverified claim. The Phase 1 pass fetched it: 91 FR 22714 (AG Order No. 6754-2026, dated April 22, 2026, effective April 28, 2026) and 91 FR 22777 (Docket DEA-1362, hearing notice). Scope, dates, the recreational carve-out, the §280E discussion and the hearing window all check out against the primary text. Three D.C. Circuit petitions confirmed on CourtListener: 26-1106 SAM, Inc. v. DOJ, 26-1130 Nebraska v. DOJ, 26-1136 New Directions Addiction Recovery Services v. Trump. This is confirmation at primary tier, not verification in full. Two elements below were not independently found and should not be read as confirmed: that the petitions were formally consolidated, and the August 17, 2026 post-hearing-brief deadline, which appears in neither notice. Both require authenticated docket access.

This moved substantially since the protocol was drafted. On April 22, 2026, DEA finalized an order (effective April 28) rescheduling cannabis from Schedule I to Schedule III — but only for two narrow categories: FDA-approved marijuana drug products, and marijuana under a state medical-marijuana license. Recreational/adult-use marijuana remains Schedule I. This is not federal legalization in any broader sense — it's a narrow reclassification that removes §280E's deduction disallowance for state-licensed medical operators specifically (recreational operators get no relief). This is actively contested: three petitions challenging the order were consolidated in the D.C. Circuit, and a separate DEA administrative hearing on broader rescheduling ran June 29–July 15, 2026, with post-hearing briefs due August 17, 2026 — any final agency action still faces further judicial review after that. Whether retroactive §280E relief happens is genuinely unresolved — the order "encouraged" Treasury to consider it, which is not a decision.

24 states (+ D.C. and territories) have legalized recreational cannabis. SAFE Banking Act — the fix for cannabis businesses' exclusion from normal banking — has passed the House seven times (2019–2022) and never gotten a Senate floor vote; a 2026 reintroduction faces the same paralysis. This is squarely a federal-statute problem no state can fix on its own, and it's the concrete mechanism keeping state-legal cannabis businesses cash-only and undercapitalized nationally.

Medicaid IMD exclusion — real workarounds exist, mostly via agency action

The exclusion (barring federal Medicaid match for residential SUD facilities over 16 beds, ages 21–64) is worked around three ways: 1115 demonstration waivers (CMS's own existing statutory authority — 38 states + D.C. have one as of April 2026, pure agency action); 42 CFR §438.6(e)'s 15-day managed-care carve-out (a pure CMS regulatory creation, no statute); and the §1915(l) state-plan option (created by the 2018 SUPPORT Act, expired 2023, made permanent by the 2024 Consolidated Appropriations Act — both of those required Congress). A full repeal of the underlying exclusion itself would need Congress.

The contingency-management ceiling — corrected, and no longer the "cheap, fast" lever this section claimed

CORRECTED 2026-08-10 by the Phase 1 verification pass (verification-log.md, headline findings 1 and 2). Two claims in the original paragraph do not survive primary text: that the $75 figure was an anti-kickback ceiling OIG could raise, and that a CM rulemaking process was already underway.

The "$75/patient/year" figure Phase 0/§4 flagged is not a statutory cap — but it is also not an anti-kickback ceiling. It is OIG's nominal-value guidance under the Beneficiary Inducements CMP (raised to $15/item and $75/aggregate-year in a December 7, 2016 policy statement), which OIG says does not apply to the anti-kickback statute at all, and which OIG says is not a CM limit: "There is no OIG-imposed $75 limitation on contingency management program incentives" (85 FR 77684, 77791–92). The 75thatactuallyboundCMprogramswasSAMHSA^′sowngrantcondition.SAMHSA^′sJanuary2025advisory(75→$750/yr) touches only its own grant programs — it doesn't bind Medicaid/commercial payers and isn't a safe-harbor change. See ws04-findings.md for the full correction.

The rulemaking is not "already underway." OIG's November 2024 solicitation is 89 FR 93545 (Nov. 27, 2024; comments closed Jan. 27, 2025) — the statutorily mandated annual notification under HIPAA §205 / 42 U.S.C. 1320a-7d, published every year (2022, 2023, 2024, and again December 2025). It does not mention contingency management. The actual CM safe-harbor proposal is RIN 0936-AA13, which the current Unified Agenda lists under Long-Term Actions with an NPRM target of July 2027 — slipped from a May 2026 target in the Spring 2025 agenda (see ws14-cm-legal-status.md).

What does survive. OIG's authority is real and pre-existing: 42 U.S.C. 1320a-7d(a)(1)(A)(i) refers back to "safe harbors issued pursuant to section 14(a) of the Medicare and Medicaid Patient and Program Protection Act of 1987," and RIN 0936-AA13's own legal-authority field cites 1320a-7d(a)(3). But the statute requires the Secretary to act "in consultation with the Attorney General" (1320a-7d(a)(1)(B)) and through notice-and-comment — so "one office can change it on its own, tomorrow" was never accurate. And a safe harbor shelters conduct from a statute; it does not repeal the statute. On the corrected record this is still a rulemaking-only path, but it is neither fast nor in motion, and A3's D2/D8 cells (legal executability 3, speed 3) are owed a re-score.

Rulemaking-vs-statute inventory

Implications for §10/§11

• §11's "rulemaking-executable items first" sequencing principle has a concrete, ranked worklist now: the CM safe-harbor fix is the single cheapest, fastest lever (OIG can do it alone, and the process is already underway); the IMD 1115-waiver pathway is proven and scalable without new legislation; Re-specified 2026-08-10 (Phase 1 for "already underway," Phase 2 for the venue). The CM safe harbor is neither the cheapest nor the fastest lever: it targets July 2027 and nothing is pending, while five states have taken CM to delivery through the same §1115 channel this bullet already identified as "proven and scalable" for IMD. The two items belong in one row, not two — §1115 demonstration authority is this filing's working rulemaking-executable lever, and CM is one of the things it has already carried. Methadone deregulation and a durable IMD fix both require Congress and should be sequenced later or run in parallel as longer-horizon items.
• §10's methadone-deregulation architecture needs to be scored knowing it requires statutory change (MOTAA or equivalent) — not achievable by SAMHSA/DEA rulemaking alone, unlike what a casual reading of the 2024 Part 8 reform might suggest.
• The cannabis rescheduling situation is live and unresolved as of this filing's Phase 0 date — the whitepaper should date-stamp any claim about cannabis's federal legal status given the active D.C. Circuit litigation and pending broader-rescheduling hearing outcome.

Confidence: Moderate-to-strong

Strong on statutory/regulatory mechanics (CSA scheduling process, anti-kickback/CMP structure, OIG's rulemaking authority, IMD waiver mechanisms) — cross-checked against multiple independent sources and, in several cases, primary regulatory text. Moderate on the most time-sensitive items (the April 2026 cannabis order's precise scope, ongoing litigation status) since several primary documents (Federal Register text, DEA.gov, CRS reports) returned access errors and the agent relied on converging law-firm client alerts rather than primary text directly — those alerts agree closely with each other, which raises confidence, but this falls short of the ideal evidence standard. Whether Treasury acts on retroactive §280E relief is explicitly flagged as unresolved, not guessed.